Acandis, founded in 2006 by Dr. Andreas and Kirsi Schuessler, is a pioneer in the neurovascular medical device industry. The company operates state-of-the-art manufacturing facilities and commercial operations in over 60 countries, employing more than 300 people. Acandis is renowned for its continuous innovation in the fields of flow diverters, rescue stenting, mechanical thrombectomy, and biologically-active device coatings. With 17 product families launched, the company has achieved market leadership in multiple geographies, driven by its commitment to improving patient outcomes and procedure ease.
Following the investment, Lauxera Capital Partners aims to accelerate commercialisation activities in direct markets and execute US clinical trials to achieve market access for key Acandis products. Additionally, the company will explore external growth opportunities to broaden its reach and deepen its portfolio.
The NautaDutilh team also included partner Jean-Marc Groelly and senior associate Isabelle Absalon from our tax practice, and senior associate Hédi Khedache-Thiriet from our Corporate M&A practice. They worked alongside the French and German offices of the international law firm McDermott Will & Emery.
